Pulmonary abnormalities in inflammatory bowel disease  by Schleiermacher, Dietlind & Hoffmann, Jörg C.
ava i l ab l e a t www.sc i enced i r ec t . com
Journal of Crohn's and Colitis (2007) 1, 61–69REVIEW ARTICLE
Pulmonary abnormalities in inflammatory
bowel disease
Dietlind Schleiermacher, Jörg C. Hoffmann ⁎Abteilung Innere Medizin I, St. Marienkrankenhaus, Ludwigshafen, Germany
Received 31 August 2007; accepted 31 August 2007⁎ Corresponding author. Abteilung Inn
621 55012232; fax: +49 621 55012795.
E-mail address: joerg.hoffmann@st
1873-9946/$ - see front matter © 200
doi:10.1016/j.crohns.2007.08.009Abstract
Extraintestinal manifestations of inflammatory bowel disease (IBD) is a common clinical problem
affecting up to half of all IBD patients; pulmonary disease, however, ranks among less common
extraintestinalmanifestations of IBD. Pulmonary disease in patientswith IBD ismost frequently drug
induced due to treatment with sulfasalazine or mesalamine leading to eosinophilic pneumonia and
fibrosing alveolitis or due to treatmentwithmethotrexate leading to pneumonitis. Recently, various
opportunistic infections have been shown to be a further important cause of pulmonary
abnormalities in those IBD patients who are treated with immunosuppressants such as anti TNF-α
monoclonal antibodies, methotrexate, azathioprine or calcineurin antagonists. In not drug related
pulmonary disease a wide spectrum of disease entities ranging from small and large airway
dysfunction to obstructive and interstitial lung disorders exist. Patients with lung disorders and
inflammatory bowel disease should be evaluated for drug-induced lung disease and opportunistic
infections prior to considering pulmonary disease as an extraintestinal manifestation of
inflammatory bowel disease.
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inflammatory bowel disease (IBD) due to treatment with
sulfasalazine, mesalamine, methotrexate or infliximab
Non-infectious cause Eosinophilic pneumonia
Eosinophilic pleura effusion
Fibrosing alveolitis
Pneumonitis
Opportunistic infections Mycobacterium tuberculosis
Pneumocystis jiroveci (carinii)
Listeria monocytogenes
Aspergillus fumigatus
Histoplasma capsulatum
Coccidioides immitis
Overwhelming infection with
Plasmodium falciparum
Cryptococcus neoformans
Cytomegalovirus
Nocardia asteroides1. Introduction
Many patients with inflammatory bowel disease (IBD) suffer
not only from bowel inflammation but also from extraintest-
inal manifestations such as pyoderma gangrenosum, erythema
nodosum, dermatitis, aphtous stomatitis, uveitis, episcleritis,
hepatitis, cholestatic liver disease, haemolytic anemia, ar-
thritis, ankylosing spondylitis, pancreatitis, thyroiditis and
pericarditis.1–3 An association between pulmonary disease and
IBD was recognized already about 40 years ago.2 While the
overall incidence of extraintestinal manifestations has been
reported to range from 21% to 41%,4 pulmonary disease in
association with IBD seems to be uncommon.
The most frequent cause of pulmonary abnormalities in
patients with IBD is drug-induced lung disease and more
recently infectious forms of lung disease due to immunosup-
pression. Drug-induced lung disease occurs most often in
patients treated with sulfasalazine or mesalamine leading to
eosinophilic pneumonia and fibrosing alveolitis and metho-
trexate leading to pneumonitis.4 Treatment with immuno-
suppressants such as anti TNF-α monoclonal antibodies,
methotrexate, azathioprine or calcineurin antagonists (e.g.
tacrolimus) can lead to various opportunistic infections.
Therefore, drug-induced lung disease as well as opportunistic
infections must be ruled out first before considering
pulmonary abnormalities as extraintestinal manifestations.
In not drug-induced disease, a wide variety of pulmonary
manifestations exist including small and large airway dysfunc-
tion.5,6 In addition, obstructive and interstitial lung disorders
have been described.2 Case reports show a large spectrum of
disease entities such as bronchial hyperresponsiveness,7 bron-
chitis and bronchiectasis,8 inflammatory tracheal stenosis,9
interstitial pneumonitis10 and bronchiolitis obliterans-organiz-
ing pneumonia.11 Moreover, pulmonary abnormalities seem to
be related to disease activity12 and occur mainly years after
the diagnosis of IBD, the incidence increasing with duration of
disease.13 Occasionally, pulmonary disease can precede the
diagnosis of IBD.3
In this article we review the pulmonary manifestations
which have been associated with IBD.
2. Drug related pulmonary abnormalities
Drug related pulmonary abnormalities occur due to treatment
with sulfasalazine,mesalamine, corticosteroids, azathioprine,
calcineurin antagonists, methotrexate or infliximab and can
be divided into opportunistic pulmonary infections secondary
to immunosuppression and drug-induced non-infectious lung
disease (Table 1).
Both, sulfasalazine and mesalamine, can induce non-
infectious lung disease which is not dose related and usually
occurs after 2 to 6 months of therapy. Rarely, drug-inducedlung disease already becomes apparent after a few days of
treatment or years after starting treatment.4 The most
frequent pulmonary pathology reported is eosinophilic
pneumonia with infiltration of lung tissue with eosinophils
and eosinophilia in the peripheral blood.14–20 Eosinophilic
pleural effusions can also occur.21,22 The second most com-
mon pulmonary pathology upon sulfasalazine or mesalamine
treatment is fibrosing alveolitis, which is a potentially lethal
drug reaction. A small number of patients with IBD and
alveolar fibrosis have been reported in the literature.23–30
Treatment with corticosteroids and withdrawal of the drug
have been shown to be successful.
Pulmonary symptoms in patients with eosinophilic pneu-
monia or fibrosing alveolitis are non-specific, the most
common symptoms being dyspnea, cough, chest pain and
fever.4 Eosinophilia was reported in about 50% of patients.31
Diffusion capacity is reduced in most patients and infiltrates
can be seen on chest X-rays. Treatment consists in drug
withdrawal and therapy with corticosteroids.4
Azathioprine and probably also 6-mercaptopurine rarely
cause interstitial pneumonitis or bronchiolitis obliterans.32–34
However, interstitial pneumonia can also be caused by infec-
tion with Pneumocystis jiroveci or Mycobacterium xenopi
although this seems to be as rare as non-infectious lung disease
with only three patients reported worldwide.35–37
Methotrexate can lead to a potentially lethal pneumoni-
tis.38 Pulmonary symptoms include dyspnea, fever and cough
as well as hypoxemia and tachypnea. Chest X-rays usually
show diffuse interstitial or mixed interstitial and alveolar
infiltrates, pulmonary function tests reveal restrictive
disease. Pneumonitis due to methotrexate therapy has not
been reported in patients with Crohn disease, however over
63Pulmonary abnomalities in IBD100 cases with this side effect of methotrexate treatment
have been described in patients with rheumatoid arthritis.38
Immunosuppression using methotrexate – similar to
azathioprine – can also lead to opportunistic lung infections
caused by Cytomegalovirus, Cryptococcus, Nocardia, P.
jiroveci or Mycobacterium tuberculosis.39–42 Even Ebstein–
Bar-virus-induced pulmonary lymphoma have been
described.43
Infliximab, an anti-TNF-α monoclonal antibody (mAb), is
increasingly used in patients with IBD. Recent data investi-
gating the use of infliximab in patients with rheumatoid
arthritis showed an increased risk of infection.44,45 The
incidence of infections was reported to be highest within 6
months after initiation of anti-TNF-α mAb therapy. Keane
et al. report 70 cases of tuberculosis in patients treated with
infliximab, 31% of which had pulmonary involvement.46
Screening for tuberculosis prior to treatment initiation is
mandatory and prophylactic tuberculostatic treatment is
recommended if latent infection is found and anti-TNF-αmAb
therapy is the only treatment option.47 Further infections
found in patients treated with TNF blockade include Pneu-
mocystis jiroveci pneumonia,48,49 histoplasmosis due to His-Figure 1 Flow chart for work-up of patientoplasma capsulatum50–52 and coccidioidomycosis due to
Coccidioides immitis.53 For diagnosis of P. jiroveci pneumonia
bronchoscopy with broncho-alveolar lavage is necessary early
in the course of the disease. The onset of symptoms of
pneumonia has been described to be early after initiation of
infliximab therapy with a mean of 21 days, moreover, the
mortality rate has been reported to be high (27%).49
Prophylaxis for P. jiroveci infection must be considered in
all patients with double or triple immunosuppression as well
as in those patients who have already had this infection.
Importantly, also treatment with systemic corticosteroids
have been reported to have more common infections with
P. jiroveci, Aspergillus, and Mycobacteria.40
Several cases of Listeria monocytogenes infections
associated with infliximab therapy in patients with Crohn's
disease have been reported.54,55 A further rare complication
of infliximab treatment is overwhelming parasitemia with
Plasmodium falciparum, which has been reported in one
case.56 Other infections associated with infliximab treat-
ment include invasive aspergillosis.57,58 Furthermore, a case
of pneumonia due to Cryptococcus neoformans in a patient
receiving infliximab has been reported.59 Because of thets with pulmonary abnormalities in IBD.
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patients treated with infliximab one might think that most
patients on infliximab might develop a lung infection at some
point. This is clearly not the case and we can only assume at
present that anti-TNF-α mAB seem to lead to a more severe
immunosuppression particularly when used together with
steroids and other immunosuppressants.
Cyclosporinemay be used for treatment of steroid resistant
ulcerative colitis. A case ofNocardia asteroides lung abscess in
patient with ulcerative colitis treated with cyclosporine has
been described.60
Since opportunistic infections of the lung and non-in-
fectious pulmonary manifestations due to treatment with
sulfasalzine, mesalamine or methotrexate are the most fre-
quent cause of the pulmonary abnormalities in IBD, drug-
induced lung disease and particularly opportunistic lung in-
fections must always be ruled out first in these patients. For
patients with IBD presenting with non-specific pulmonary
symptoms we propose the diagnostic work up as demonstrated
in Fig. 1.
3. Pulmonary abnormalities not related to drug
treatment
When pulmonary abnormalities are not related to drug
treatment various forms have been described in patients
with IBD and in one single patient multiple sites in the lung
can be involved. In this section we will discuss pulmonary
function abnormalities first, thereafter various pulmonary
manifestations according to their thoracic localisation (see
Table 2), and finally autoimmune and other pulmonaryTable 2 Pulmonary abnormalities reported in association
with IBD without drug-induced disease
Pulmonary function
abnormalities
Restrictive
Obstructive
Diffusion abnormalities
Bronchial hyperresponsiveness
Hyperinflation
Upper airways Epiglotitis
Tracheobronchitis
Large airways Bronchiectasis
Acute/chronic bronchitis
Chronic bronchial suppuration
Small airways Bronchiolitis
Bronchiolitis obliterans
Bronchiolitis obliterans organizing
pneumonia
Interstitial disease Nonspecific interstitial pneumonia
Fibrosing alveolitis
Eosinophilic pneumonia
Autoimmune disease Wegener granulomatosis
Pulmonary vasculitis
Churg–Strauss syndrome
Microscopic polyangitis
Other pulmonary
manifestations
Necrobiotic nodules
Pleuritis
Fistulae (colobronchial,
esophagopulmonary)diseases associated with IBD which cannot be classified ac-
cording to their localisation.
3.1. Pulmonary function abnormalities
Various studies testing pulmonary function in patients with IBD
have revealed a spectrumof abnormalities including restrictive
disease, obstructive disease, bronchial hyperresponsiveness
and hyperinflation as well as a decreased diffusion capacity of
the lung. There is evidence thatmore than 50% of patients with
ulcerative colitis have pulmonary function impairment without
clinical or radiologic findings.61 Only few studies have shownno
difference in pulmonary function test between patients with
and without IBD62 and obstructive pulmonary disease has also
been reported in patientswithulcerative colitis as compared to
control subjects.63 More frequently a decrease in diffusion
capacity of the lung has been described in patients with IBD as
compared to control subjects.64 This phenomenon has been
reported to be more accentuated during periods of active
disease as compared to periods of remission.5 Herrlinger et al.
also found an influence of disease activity but did not
emphasize measurement of diffusion capacity as a specific
marker for disease activity since values for forced expiratory
volume in 1 sec and inspiratory vital capacity were also de-
creased during periods of active disease.65 Studies assessing
functional residual capacity in patients with Crohn disease
have shown evidence of hyperinflation66,67 and were also able
to show an association between active disease and hyperinfla-
tion. Other investigations have revealed bronchial hyperre-
sponsiveness in patients with IBD, although further studies
were not able to confirm these results.68,69
3.2. Upper airway abnormalities
Only few studies report involvement of the upper airways in
overall 15 patients with IBD.3,4 Symptoms described in these
patients include shortness of breath, cough anddysphonia. The
diagnosis of upper airway stenosis can be made by radiologic
examinations, pulmonary functions testing showing evidence
of pulmonary obstruction and laryngoscopic examination. In all
patients with upper airway involvement there was evidence of
tracheal disease, but laryngeal and glottic involvement was
also reported. Rickli et al. describes a case of severe inflam-
matory upper airway stenosis due to pseudotumorous swelling
of the larynx, trachea and main bronchi.70
3.3. Large airway abnormalities
Bronchiectasis is the most common pulmonary disease found
in IBD patients. Bronchiectasis is an irreversible dilation of
bronchioles which leads to coughing and abnormal amounts
of sputum. This pulmonary abnormality has been reported in
up to 66% of patients with IBD and pulmonary disease.3 The
second most common large airway disease in IBD patients is
chronic bronchitis, further abnormalities include suppura-
tive large airway disease and acute bronchitis.
Though an association between IBD and bronchiectasis has
been reported in various studies, the pathogenesis still
remains unclear. Histological examination of bronchial and
colonic tissue shows similar changes with non-specific in-
flammation. Butland et al. propose an autoimmune process
65Pulmonary abnomalities in IBDsince most of their patients had a positive family history of
autoimmune disease, positive antinuclear antibodies and
anti-smooth-muscle antibodies.71 Kirsner et al. propose that
common antigens synthesize both the lung and gut associated
lymphoid tissue and that this can lead to a similar
inflammatory response in both.72,73
Therapy of pulmonary abnormalities in patients with IBD
has been described in case reports. Surgery of the colon is
not recommended for treatment of airway disease, however,
inhaled or systemic corticosteroids are recommended as first
line therapy.2,70,74 Ineffectiveness of inhaled corticosteroids
may be due to airways filled with inspissated secretions in
which case either topical corticosteroids via BAL or systemic
corticosteroids are recommended.73
3.4. Small airway abnormalities
Involvement of the small airways in patients with IBD has been
detected by high-resolution computed tomography.8 These
abnormalities seemtooccur earlier in the courseof the disease
and at a younger age than large airway disease.75 Moreover,
small airway disease is more frequently apparent before
the onset of IBD than other airway diseases.76 Bronchiolitis is
the most frequently detected disease among small airway
diseases.2,75–79 Histological examination of pulmonary tissue
shows peribronchiolar granuloma formation and, less fre-
quently, peribronchiolar inflammation with neutrophils or
lymphocytes and plasma cells, concentric small airway fibrosis
and diffuse panbronchiolitis.3
Bronchiolitis obliterans organizing pneumonia (BOOP) has
also been described in patients with IBD.64,80,81 BOOP can be
associated with other autoimmune diseases e.g. rheumatoid
arthritis, lupus and Wegener granulomatosis. Presenting
symptoms with cough and dyspnea are non-specific. Systemic
steroids are recommended for treatment but BOOP may also
remit without treatment in a minority of cases.3,4
3.5. Interstitial disease
Interstitial lung disease in patients with IBD is usually due to
drug therapy with mesalamine and sulfasalzine, less common
azathioprine or methotrexate. A small number of cases with
interstitial lung disease have been described which were not
related to drug therapy. The pathology described in these
cases include nongranulomatous interstitial diffuse lung
disease, mild to severe interstitial fibrosis and desquamative
interstitial pneumonitis.82–87 Patients with IBD and inter-
stitial lung disease were treated with steroids or immuno-
suppressive agents such as cyclosporine and azathioprine. In
one case where no response could be achieved with these
drugs mycophenolate was used successfully.88
3.6. Autoimmune disease
A small number of caseswith IBD andpulmonary vasculitis have
been reported.2,89–95 Pulmonary disease in these patients was
not due to drug reactions. Symptoms with cough and dyspnea
were non-specific and chest X-ray films showed bilateral
infiltrates or nodules. Other entities include Churg–Strauss
syndrome,96 microscopic polyangitis and Wegener granuloma-
tosis.97 In most cases corticosteroids were administeredfor treatment. On the other hand, intestinal involvement of
Wegener granulomatosis, a pulmonary vasulitis, has been
reported in few cases.98–106 Symptoms such as bloody di-
arrhea, abdominal pain and intestinal perforation have been
described, and biopsy is essential for diagnosis.
Antineutrophil cytoplasmatic antibodies are found in
many forms of vasculitis. Whereas p-ANCA is present in
patients with microscopic polyarteritis and other autoim-
mune diseases, ANCA with a snowdrift pattern has been
detected in patients with ulcerative colitis.107,108 This points
towards a common autoimmune component in both diseases.3.7. Other pulmonary manifestations
Necrobiotic nodules are a very rare pulmonary abnormality in
patients with IBD and have been reported in two cases.109,110
A small number of cases with pleuritis, i.e. pleural effusion,
have been described in patients with IBD.2,111–113 Symptoms in
these patients, who are usually young, male and have ulcer-
ative colitis, included dyspnea and chest pain.3 Mostly pleural
effusions are unilateral and, when examined, prove to be
exudates. Treatment with corticosteroids was reported to be
successful. Pericardial involvement has also been reported,
and in an even smaller number of cases both pleural and
pericardial involvement has been described.
Patients with Crohn disease can develop fistulae to any
neighbouring structure. Patients with colobronchial fistulae
and ileobronchial fistulae have been reported.114–119 These
patients present with pneumonia and pleural effusions.
Sputum culture with evidence of enteric pathogens points
towards the diagnosis of fistulae. Usually lung surgery is
necessary for treatment. In very rare cases of esophageal
involvement in patients with Crohn disease pulmonary fistulae
have been reported.120–122 In these patients surgical treat-
ment is also necessary. When patients with Crohn disease
develop chronic pneumonia and sputum culture shows enteric
pathogens pulmonary fistulas can be the underlying cause.
Sarcoidosis and Crohn disease are both idiopathic granu-
lomatous diseases which have similar ocular, dermatologic
and joint manifestations in common. An increased CD4:CD8
ratio has been found in alveolar lavage from patients with
sarcoidosis and in patients with Crohn disease.123,124 These
findings point towards a possible common pathogenesis of
both diseases. 53 cases of patients with sarcoidosis and Crohn
disease have been reported in a review of the literature of
2007.3 Most of these cases were treated with corticosteroids,
but recent reports show that treatment with infliximab (anti-
TNF-α) can be successful in the treatment of Crohn disease
and sarcoidosis as well.125,126 This finding further supports a
common pathogenesis of both diseases.
Alpha-1-antitrypsin deficiency leads to pulmonary emphy-
sema and hepatic dysfunction. A small number of patients
withα1-antitrypsin deficiency and IBD have been reported,127
and studies analysing abnormal α1-antitrypsin alleles in
patients with IBD have shown a higher prevalence of PiZ
carriers among patients with IBD as compared to the general
population.128 PiZ carrier status was associated with
increased severities of colitis and an effect of smoking with
local tissue damage in the gastrointestinal tract via changed
neutrophil elastase regulation in α1-antitrypsin deficiency
was suggested.3
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disease. Both arterial and venous thrombosis have been
described with an incidence between 1 and 8%.129–135 Deep
venous thrombosis and pulmonary emboli (see Fig. 2) have
been observed in patients with IBD, but IBD itself has also been
associated with a hypercoagulable state since deep venous
thrombosis has been described in patients with inactive IBD.
This finding points towards a thrombotic risk in patients with
IBD which is not related to disease activity or therapy. How-
ever, the pathogenesis of this increased thrombotic risk in
patients with IBD remains unclear. The prevalence of activated
proteinC resistance or factor V Leidenmutation is not higher in
patients with IBD than in the general population.131 Anti-
cardiolipin antibody levels were shown to be elevated in
patients with IBD, but seem to play no role in the pathogenesis
of thromboembolic disease in this setting.136 Hyperhomocys-
teinemia as a risk factor for thrombosis which can be due to
genetic factors, medications such as corticosteroids, metho-
trexate and sulfasalazine and nutritional deficiencies has been
described in patients with IBD.137 Other laboratory markers
indicating an activation of the coagulation system have been
found in some patients with IBD, but the significance of these
findings is not clear. An exact molecular mechanism for the
hypercoagulable state in patients with IBD, however, needs
further investigations.Figure 2 Thromboembolism in IBD. Shown is TC scan images of a
patient with a history of ulcerative colitis presenting with a dorso-
lateral pneumonia (A) due to pulmonary emboli as shown in (B).Asthma has been shown to have a higher prevalence
among patients with IBD as compared to control subjects.138
Furthermore, a more severe course of asthma has been
described in patients with IBD. This was shown in a study by
Kanazawa et al., where patients with ulcerative colitis and
asthma had increased airway obstruction and a 20% decrease
of FEV1 on metacholine challenge as compared to patients
with asthma and without ulcerative colitis.139 Increased
inflammation, increased vascular endothelial growth activity
and vascular permeability in patients with asthma and
ulcerative colitis was proposed.
4. Conclusions
Pulmonary abnormalities in patients with inflammatory bowel
disease can be divided into frequent drug related and not drug
related disorders.
Drug related pulmonary abnormalities include disorders
which are directly induced by sulfasalzine, mesalamine,
methotrexate or rarely azathioprine and opportunistic lung
infections with pulmonary manifestations due to immuno-
suppressive treatment with anti TNF-α monoclonal antibo-
dies, methotrexate, azathioprine or calcineurin antagonists.
In patients with IBD, screening for tuberculosis prior to
treatment is mandatory and prophylactic tuberculostatic
treatment is recommended if anti TNF-α monoclonal anti-
bodies are the only treatment option. Prophylactic treatment
of P. jiroveci must be considered in patients with double or
triple immunosuppression and in those patients who have
already had this infection.
Not drug related pulmonary abnormalities may be con-
sidered as true extraintestinal manifestations of inflamma-
tory bowel disease and include a wide variety of disease
entities. The most common abnormality of these is
bronchiectasis.
Non-infectious lung disorders due to treatment with sulfasa-
lazine, mesalamine or methotrexate and opportunistic infec-
tions of the lung must be ruled out first before extraintestinal
manifestations of inflammatory bowel disease are considered.
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